Drug Discovery

actavis-new-drug-application-nda-for-progestin-only-transdermal-contraceptive-patch-norethindrone-transdermal-delivery-system-gets-fda-nod

Actavis 'pregnancy preventer' gets FDA nod

  • US
  • |
  • News

Singapore: US FDA has accepted Actavis' New Drug Application (NDA) for a progestin-only transdermal contraceptive patch (Norethindrone Transdermal Delivery System) for use by women to prevent pregnancy. The acceptance of the NDA for... Read more

gilead-leukemia-study-gets-complete-repsonse

Gilead leukemia study gets complete response


  • Australia
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Gilead Sciences' phase II study (Study 101-08) evaluating idelalisib (formerly GS-1101), an investigational, targeted,... Read more

bioduro-opens-discovery-lab-in-shanghai

BioDuro opens discovery lab in Shanghai


  • China
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: BioDuro, a PPD Company, has opened a new state-of-the-art laboratory in Shanghai, China, strengthening its ability... Read more

nektar-therapeutics-nktr-214-targets-il-2-receptor-complex-and-activates-il2r-subtype-which-promotes-tumor-killing-by-the-body-s-own-immune-system

Nektar's therapy helps the body kill its own cancer

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: US-based Nektar Therapeutics has revealed positive preclinical data for NKTR-214, a novel cancer immunotherapy which targets... Read more

viralytics-cavatak-is-well-tolerated-in-phase-i-trials

Viralytics multi-cancer drug shows +ve results

  • Australia
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Viralytics has finalized the clinical study report on the phase I evaluation of Cavatak, which is administered intravenously... Read more

gilead-s-sofosbuvir-anda-if-approved-by-the-us-fda-would-reduce-treatment-time-from-24-to-48-weeks-to-12-to-16-weeks

Gilead hepatitis drug to axe treatment time by half

  • US
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Gilead Sciences has submitted a New Drug Application (NDA) to the US FDA for approval of sofosbuvir, a once-daily oral nucleotide... Read more

astar-gsk-develop-medicines-for-emerging-markets

A*STAR, GSK develop medicines for emerging markets

  • Singapore
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a five-year strategic agreement... Read more

prana-biotechnology-s-phase-ii-trial-for-huntington-reach2hd-and-alzheimer-s-disease-imagine-shows-that-37-percent-have-well-tolerated-and-are-demonstrating-pleasing-retention-rates-and-compliance

Prana Alzheimer's trial shows +ve results

  • Australia
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 1 Comment

Singapore: Prana Biotechnology reported on the progress of its lead development asset PBT2, which is in phase II trials for Huntington disease... Read more

oxycodone-patch-resumes-clinical-development

Oxycodone patch resumes clinical development

  • Australia
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Australian drug delivery technology company, Phosphagenics, will be returning to the clinic with its oxycodone TPM transdermal... Read more

vaxinnate-gets-usd2

NIH gives $2.2 mn to VaxInnate for dengue vaccine

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has provided funds worth... Read more

astellas-to-pay-ambrx-close-to-usd300-million-for-its-antibody-drug-conjugates-adcs-in-oncology

Astellas to pay $300 mn for cancer drug conjugates

  • Japan
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Japan's Astellas Pharma has collaborated with US-based Ambrx for the discovery and development of novel antibody drug conjugates... Read more

inventor-of-glivec-dr-alex-matter-winner-of-the-8th-annual-szent-gy-rgyi-prize-for-progress-in-cancer-research

Glivec inventor wins Szent-Györgyi Prize

  • Singapore
  • |
  • Influencers
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Professor Alex Matter, CEO, Experimental Therapeutics Centre (ETC), A*STAR, Singapore, has been awarded the 8th Annual Szent-Györgyi... Read more

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X